Panelists discuss how data systems and registries should focus on improving care quality rather than just reimbursement, with patient empowerment strategies that encourage individuals to advocate for better treatments like de-prescribing harmful medications.
Data Systems and Continuous Care
Effective diabetes and obesity management requires moving beyond episodic care toward continuous, comprehensive monitoring using registries, analytics, and population health tools. The goal should be providing highest quality care rather than simply meeting reimbursement requirements, though both objectives can align when properly implemented. Healthcare systems need division-level population health services that give clinicians access to panel management tools for tracking patient outcomes.
Leveraging data effectively requires mechanisms for improvement beyond simply identifying problems. Patient empowerment strategies, such as reaching out to patients directly about medication optimization opportunities, can be more effective than only approaching busy primary care physicians. This approach activates patients to engage in discussions with their providers about treatment modifications and improvements.
The integration of clinical analytics with patient outreach creates opportunities for proactive rather than reactive care management. By identifying patients who could benefit from specific interventions and engaging them directly, healthcare systems can improve quality while supporting rather than burdening primary care providers. This systematic approach to continuous care management represents a significant advancement from traditional episodic visit-based models.
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More